Regenesome Inc. ” Raises 80 Million Yen in Pre-Seed Round
Regenesome Inc., a subsidiary of Space Seed Holdings Inc., has raised a total of 80 million yen in a Pre-Seed round through the issuance of J-KISS-type stock options, with Japan System Techniques Co., Ltd. (JAST) (Headquarters: Kita-ku, Osaka; President and CEO: Takeaki Hirabayashi) as the underwriter. This marks the first close for Regenesome, which plans to seek additional financing through loans from financial institutions.
Regenesome is a research and development-focused startup dedicated to advancing anti-aging technology, with a primary focus on exosome research. Driven by the mission to address future challenges brought on by aging through biotechnological innovation, Regenesome upholds the following Mission, Vision, and Values:
Mission:To deliver anti-aging technologies applicable on Earth and essential for extending human life to the Moon by 2040.
Vision:To demonstrate viable anti-aging technology for healthspan by 2030.
Value:Building a foundation of scientific knowledge on exosomes. Establishing networks for the practical application of space sciences. Conducting R&D to tackle health-related challenges, including anti-aging solutions, both on Earth and in space.
Exosomes are extracellular vesicles (40-150 nm) originating from endosomes, known for their role in transporting and processing materials absorbed outside the cell. Found across various cell types, exosomes contain RNA, DNA, lipids, and proteins essential for cellular communication, facilitating intercellular signaling that regulates various physiological and pathological processes. Notably, exosomes play a role in modulating immune responses by adjusting interactions between immune cells, influencing inflammatory responses, and controlling immune disorders. Additionally, exosomes are released by cancer cells, carrying factors that contribute to cancer proliferation, angiogenesis, and immune suppression. Exosomes also hold potential in regenerative medicine by transporting growth factors and microRNAs that aid in tissue repair and regeneration.
Regenesome conducts omics analysis on cultured cells and human clinical trials under different environmental conditions, meticulously analyzing exosomes to explore their production and functionality within organisms. Through these research efforts, Regenesome aims to uncover knowledge on anti-aging methods using exosomes, contributing to advancements in space medicine as well as enhancing medical technologies on Earth. Key business initiatives include:
1. Development of supplements, food products, and cosmetics utilizing exosomes.
2. Development of new products and services based on substances found in cells.
3. Intellectual property management.
4. Consulting services for management, sales, and research.
5. Planning, producing, and managing various events.
6. Photography and video services, including production and sales.
7. All related services and activities.
As society’s demand for longevity intensifies, the potential of nanoparticles, including exosomes, is expanding in medical and research fields. In the realm of space development, the need for anti-aging technology to enable prolonged space missions is increasingly apparent. Recognizing these demands, Space Seed Holdings, participating in the SPACE FOODSPHERE team and the Healthspan Program of the U.S.-based XPRIZE Foundation, established Regenesome in July 2024 to realize anti-aging measures through nanotechnology.
By leveraging the relationship assets of Space Seed Holdings, Regenesome aims to conduct a Proof of Concept (POC) within 18 months. Following this, preparations for the next development phase will commence, ultimately striving to reduce societal burdens related to aging and expand human living environments beyond Earth.
